share_log

康希諾生物：海外監管公告

CANSINOBIO: An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section

香港交易所 ·  Apr 11 07:34
Summary by Moomoo AI
康希諾生物股份公司（「康希諾」）於2024年4月11日發布海外監管公告，公佈了由中信證券股份有限公司（「中信證券」）出具的關於康希諾首次公開發行股票並在科創板上市的保薦總結報告書。報告書指出，康希諾於2020年8月13日在上海證券交易所科創板成功上市，公開發行人民幣普通股24,800,000股，每股發行價格為209.71元人民幣。募集資金總額達497,946.51萬元人民幣，超募資金達397,946.51萬元。中信證券作為保荐機構，對康希諾進行了持續督導，並於2023年12月31日結束督導期。報告中提到，康希諾在募集資金使用上進行了部分變更，以適應市場需求和公司戰略發展目標。然而，康希諾2022年度及2023年度業績出現下滑，主要由於新冠疫苗市場需求大幅下降，導致銷售收入減少，並計提了相關資產的減值準備。中信證券在其持續督導職責期間，對康希諾的生產經營情況進行了關注，並督促公司管理層履行企業管理經營責任。
康希諾生物股份公司（「康希諾」）於2024年4月11日發布海外監管公告，公佈了由中信證券股份有限公司（「中信證券」）出具的關於康希諾首次公開發行股票並在科創板上市的保薦總結報告書。報告書指出，康希諾於2020年8月13日在上海證券交易所科創板成功上市，公開發行人民幣普通股24,800,000股，每股發行價格為209.71元人民幣。募集資金總額達497,946.51萬元人民幣，超募資金達397,946.51萬元。中信證券作為保荐機構，對康希諾進行了持續督導，並於2023年12月31日結束督導期。報告中提到，康希諾在募集資金使用上進行了部分變更，以適應市場需求和公司戰略發展目標。然而，康希諾2022年度及2023年度業績出現下滑，主要由於新冠疫苗市場需求大幅下降，導致銷售收入減少，並計提了相關資產的減值準備。中信證券在其持續督導職責期間，對康希諾的生產經營情況進行了關注，並督促公司管理層履行企業管理經營責任。
CONXINO BIO CORPORATION (“CONXINO”) ISSUED AN OVERSEAS REGULATORY NOTICE ON APRIL 11, 2024, ANNOUNCING A SUMMARY REPORT OF RECOMMENDATION BY CITIC SECURITIES LIMITED (“CITIC SECURITIES”) REGARDING CONCHINO'S INITIAL PUBLIC OFFERING OF SHARES AND LISTING ON SCIENTBOARD. The report noted that Conchino successfully listed 24,800,000 shares of RMB Ordinary Shares on August 13, 2020 on the Shanghai Stock Exchange's Scientboard, with a public offering price of RMB209.71 per share. The total amount of funds raised was RMB 497,946.51 million, and the over-fund reached RMB 397,946.51 million. CITIC Securities, as a proxy, conducted ongoing supervision of Conchino and ended the supervision period on December 31, 2023. The report mentions that Conchino has made some changes to its use of fundraising to adapt to market needs and the company's...Show More
CONXINO BIO CORPORATION (“CONXINO”) ISSUED AN OVERSEAS REGULATORY NOTICE ON APRIL 11, 2024, ANNOUNCING A SUMMARY REPORT OF RECOMMENDATION BY CITIC SECURITIES LIMITED (“CITIC SECURITIES”) REGARDING CONCHINO'S INITIAL PUBLIC OFFERING OF SHARES AND LISTING ON SCIENTBOARD. The report noted that Conchino successfully listed 24,800,000 shares of RMB Ordinary Shares on August 13, 2020 on the Shanghai Stock Exchange's Scientboard, with a public offering price of RMB209.71 per share. The total amount of funds raised was RMB 497,946.51 million, and the over-fund reached RMB 397,946.51 million. CITIC Securities, as a proxy, conducted ongoing supervision of Conchino and ended the supervision period on December 31, 2023. The report mentions that Conchino has made some changes to its use of fundraising to adapt to market needs and the company's strategic development goals. However, Concino's 2022 and 2023 results showed a decline, mainly due to a significant drop in demand for the COVID-19 vaccine market, resulting in lower sales revenue, and a write-down of related assets. CITIC Securities has kept a close eye on Conchino's production and operations and encouraged management to fulfill its corporate governance responsibilities during its ongoing supervisory role.

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more